1. US Food and Drug Administration. FDA and European Medicines Agency strengthen collaboration in pharmacovigilance area. [Press release; 19 Feb 2014]. Available at: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm386372.htm . Accessed 20 Dec 2014
2. European Medicines Agency. European Medicines Agency and US Food and Drug Administration strengthen collaboration in pharmacovigilance area. [Press release; 19 Feb 2014]. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2014/02/news_detail_002028.jsp&mid=WC0b01ac058004d5c . Accessed 20 Dec 2014
3. http://www.ema.europa.eu/ema/index.jsp?curl=pages/partners_and_networks/document_listing/document_listing_000228.jsp&mid=WC0b01ac058003176e#section1 . Accessed 20 Dec 2014
4. European Medicines Agency. Pharmacovigilance legislation. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/general/general_content_000491.jsp&mid=WC0b01ac058058f32d . Accessed 20 Dec 2014
5. Arlett P, Portier G, de Lisa R, Blake K, Wathion N, Dogne JM, Spooner A, Raine J, Rasi G. Proactively managing the risk of marketed drugs: experience with the EMA Pharmacovigilance Risk Assessment Committee. Nat Rev Drug Discov. 2014;13(5):395–7.